OMND — Optimind Pharma Share Price
Last trade - 00:00- CA$0.58m
- CA$1.12m
- CA$0.17m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.1 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 4.24 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -1335.8% | ||
| Return on Equity | -87.93% | ||
| Operating Margin | -1190.95% | ||
Financial Summary
| Year End 28th Feb | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | n/a | n/a | n/a | n/a | 0.17 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Optimind Pharma Corp. is a Canada-based emerging provider of psychedelic therapies for the masses. The Company helps people suffering from post-traumatic stress disorder (PTSD), anxiety, depression and other mental illnesses and disabilities by providing ketamine-assisted-treatment and other psychedelic-enhanced-psychotherapy modalities. The Company also partnered with developers of psilocybin-associated treatments and products to further expand its treatment and program offerings. Its treatment programs are designed based on scientific research and specific modalities used in many different therapeutic practices. Each treatment program combines the use of psychedelic medicine with therapeutic processing and integration. It has two different types of treatments. Monotherapy and assisted therapy, all based on a Ketamine capsule. The effects are felt about 30 minutes after, and within two hours of taking the medicine, cognition is resorted to normal.
Directors
- Timothy Elliott CHM
- Norman Holton CEO
- Jock Graham DRC
- Richard Elliott IND
- Kenneth Heuchert IND
- Michael Mcvea IND
- Last Annual
- February 28th, 2023
- Last Interim
- November 30th, 2023
- Incorporated
- January 5th, 2022
- Public Since
- March 17th, 1998
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Canadian Securities Exchange
- Shares in Issue
- 116,888,491
- Address
- 642 Richmond St, LONDON, N6A 3G6
- Web
- https://optimindpharma.com/
- Phone
- Auditors
- DNTW Toronto LLP
Upcoming Events for OMND
Similar to OMND
Albert Labs International
Canadian Securities Exchange
Algernon Pharmaceuticals
Canadian Securities Exchange
Alpha Cognition
Canadian Securities Exchange
Asep Medical Holdings
Canadian Securities Exchange
Awakn Life Sciences
Canadian Securities Exchange
FAQ
As of Today at 22:30 UTC, shares in Optimind Pharma are trading at CA$0.01. This share price information is delayed by 15 minutes.
Shares in Optimind Pharma last closed at CA$0.01 and the price had moved by -75% over the past 365 days. In terms of relative price strength the Optimind Pharma share price has underperformed the Toronto Stock Exchange 300 Composite Index by -77.48% over the past year.
There is no consensus recommendation for this security.
Optimind Pharma does not currently pay a dividend.
Optimind Pharma does not currently pay a dividend.
Optimind Pharma does not currently pay a dividend.
To buy shares in Optimind Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$0.01, shares in Optimind Pharma had a market capitalisation of CA$0.58m.
Here are the trading details for Optimind Pharma:
- Country of listing: Canada
- Exchange: CNX
- Ticker Symbol: OMND
Based on an overall assessment of its quality, value and momentum Optimind Pharma is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Optimind Pharma. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -67.5%.
As of the last closing price of CA$0.01, shares in Optimind Pharma were trading -93.57% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Optimind Pharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Optimind Pharma's management team is headed by:
- Timothy Elliott - CHM
- Norman Holton - CEO
- Jock Graham - DRC
- Richard Elliott - IND
- Kenneth Heuchert - IND
- Michael Mcvea - IND